Scientists have developed a new molecule that breaks down beta-amyloid plaques by binding to excess copper in the brain. The treatment restored memory and reduced inflammation in rats, while also proving non-toxic and able to cross the blood–brain barrier. Because it’s far simpler and potentially cheaper than existing drugs, researchers are now pursuing partnerships to begin human trials.

Researchers discovered that chronic inflammation fundamentally remodels the bone marrow, allowing mutated stem cell clones to quietly gain dominance with age. Reprogrammed stromal cells and interferon-responsive T cells create a self-sustaining inflammatory loop that weakens blood production. Surprisingly, the mutant cells themselves may not be the main instigators.

A specially engineered antibody that can infiltrate kidney cysts has shown the ability to block key growth signals driving polycystic kidney disease. Early mouse studies suggest it may halt or even reverse cyst expansion without harming healthy tissue.

Microplastics—tiny particles now found in food, water, air, and even human tissues—may directly accelerate artery-clogging disease, and new research shows the danger may be far greater for males. In mice, environmentally realistic doses of microplastics dramatically worsened plaque buildup, altered key vascular cells, and activated harmful genes linked to inflammation and atherosclerosis, all without changes to weight or cholesterol.

Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may help create treatments that keep the benefits of weight loss while reducing unwanted side effects.